US 11,752,139 B2
Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancer
Min-Fun Rudolf Kwan, Summit, NJ (US); E. Douglas Kramer, Stamford, CT (US); David Lawrence Cutler, Moorestown, NJ (US); Johnson Yiu-Nam Lau, Houston, TX (US); and Wing Kai Chan, Hong Kong (CN)
Assigned to Athenex HK Innovative Limited, Sha Tin (HK)
Filed by Athenex HK Innovative Limited, Sha Tin (HK)
Filed on Dec. 16, 2019, as Appl. No. 16/715,753.
Claims priority of provisional application 62/846,829, filed on May 13, 2019.
Claims priority of provisional application 62/780,110, filed on Dec. 14, 2018.
Prior Publication US 2020/0188363 A1, Jun. 18, 2020
Int. Cl. A61K 31/435 (2006.01); A61K 31/4745 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01)
CPC A61K 31/435 (2013.01) [A61K 31/4745 (2013.01); A61P 35/00 (2018.01)] 16 Claims
 
1. A method for treating cancer in a subject in need thereof, comprising:
a. oral administration of irinotecan at an amount of about 5 mg/m2 to about 10 mg/m2, about 15 mg/m2, about 20 m2, about 25 mg/m2, or about 30 mg/m2 to the subject once a day and for 1-7 times a week; and
b. oral administration of Compound A:

OG Complex Work Unit Chemistry
to the subject once a day and for 1-7 times a week, and
wherein Compound A is administered simultaneously with or prior to the irinotecan.